Cancer Vaccine Moves Closer to FDA Approval

With the news of Dendreon Corporation's announcement yesterday at the annual meeting in Chicago of the American Urological Association that its investigational active cellular immunotherapy for advanced prostate cancer, PROVENGE (sipuleucel-T), extended patient survival by 4.1 months and increased 3-year survival by 38 percent compared to placebo, the field of tumor immunology has taken a significant leap forward as this, the first active cellular immunotherapy shown in a phase III clinical trial to benefit patients, moves closer to FDA approval.

According to experts in the field of tumor immunology, this is an important milestone achievement--within the scope of the history of tumor immunology and the decades of effort to bring effective cancer immunotherapies to patients, the impact of PROVENGE specifically on prostate cancer therapy today, and the broader import this has and as it bears on cancer vaccine discovery and development efforts currently underway within academic and industry domains.

The Cancer Research Institute, a non-profit organization the supports and coordinates laboratory and clinical efforts leading to the immunological treatment, control, and prevention of cancer, is a global leader in cancer vaccine development. The CRI/LICR Cancer Vaccine Collaborative--a centralized network of more than 20 top academic clinical trial sites with immunological monitoring capability engaged in single-variable, first-in-man cancer vaccine studies, formed in partnership with the Ludwig Institute for Cancer Research Ltd--and its Cancer Vaccine Consortium--a membership association of more than 60 pharmaceutical and biotechnology companies and academic institutions who share a common goal of making cancer vaccines part of the standard-of-care for cancer patients--together comprise the world's leading experts in cancer vaccine discovery and development from both academia and industry.

Cancer Research Institute can provide expert commentary on the importance of the PROVENGE study results and what they mean for the field of tumor immunology, for cancer patients, and for the future of cancer therapy, as well as key challenges still facing the field, including vaccine reagent access, intellectual property concerns, regulatory issues, protocol design, RECIST criteria, and strategies that work to bridge the divide between academic and industry interests.

Suggested Expert:

Lloyd J. Old, M.D.

Lloyd J. Old, M.D., is chairman of the Board of Directors of the Ludwig Institute for Cancer Research Ltd. Previously, he was director and chief executive officer of the Ludwig Institute. He has been associated with the Memorial Sloan-Kettering Cancer Center since 1958, first as a research fellow. He was appointed associate director of research in 1973 of Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and Allied Diseases and was named the William E. Snee Chair of Cancer Immunology in 1983.

Lloyd J. Old, M.D., is one of the pioneers in tumor immunology, having made some of the most important contributions to that field from both the lab bench and the board room table. He is one of the most highly cited researchers in the field, and is an international award-winning scientific luminary who has helped to forge alliances among academic and industry interests in order to accelerate the scientifically prudent advancement of cancer vaccines.

For a more detailed biography of Dr. Old, visit:
http://www.cancerresearch.org/board/Lloyd-Old.html

For a description of Dr. Old's key scientific contributions, visit:
http://www.cancerresearch.org/Programs.aspx?id=2290

Views: 33

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

"Destroying the New World Order"

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

TOP CONTENT THIS WEEK

Latest Activity

James Roberts posted a video

Ann Coulter - Part 1 of 2 | The Eric Metaxas Radio Show

Ann Coulter pulls no punches giving her thoughts on the Trump presidency so far, including building the wall, nominating Supreme Court justices, and generall...
10 minutes ago
James Roberts favorited Diana's photo
12 minutes ago
James Roberts favorited Diana's photo
12 minutes ago
James Roberts favorited Diana's photo
13 minutes ago
James Roberts commented on Diana's photo
Thumbnail

gun-control

"Correct answer: I have much less ammo left, and they have to pry them from my cold, dead hands."
13 minutes ago
James Roberts favorited Diana's photo
14 minutes ago
James Roberts favorited Diana's photo
14 minutes ago
rlionhearted_3 favorited Less Prone's photo
21 minutes ago
rlionhearted_3 favorited Diana's photo
24 minutes ago
Lori replied to MAC's discussion Polar bear expert purged
"The issue is environmental poison from human inbred populations from their raping slums. They need…"
28 minutes ago
Lori replied to Mrs. Tif Morgan's discussion Richard Huckle, 33: Pedophile Who Assaulted Nearly 200 Kids
"I was one of their victims. They use brain fragmenting. The adrenochrome disorder the victims have…"
43 minutes ago
Diana posted photos
1 hour ago
Diana favorited Chris of the family Masters's photo
1 hour ago
Diana favorited Less Prone's photo
1 hour ago
Diana favorited cheeki kea's photo
1 hour ago
JoeG favorited Less Prone's photo
1 hour ago

© 2019   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted